EP Patent

EP1443928B1 — Treatment of neurodegenerative diseases and cancer of the brain

Assigned to Memorial Sloan Kettering Cancer Center · Expires 2011-07-27 · 15y expired

What this patent protects

A composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the following structure: or a pharmaceutically acceptable salt or hydrate thereof, and a Pharmaceutical acceptable carrier or diluent, for use in the treatment of brain cancer in a mammal, wherein t…

USPTO Abstract

A composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the following structure: or a pharmaceutically acceptable salt or hydrate thereof, and a Pharmaceutical acceptable carrier or diluent, for use in the treatment of brain cancer in a mammal, wherein the composition is formulated for oral administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP1443928B1
Jurisdiction
EP
Classification
—
Expires
2011-07-27
Drug substance claim
No
Drug product claim
No
Assignee
Memorial Sloan Kettering Cancer Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.